September 18, 2020
This week, members of our Therigy team had the opportunity to present a new poster abstract at the 2020 NASP Annual Meeting & Expo, which was held virtually from September 14-18. Lily Duong, PharmD, RPh, and Chief Clinical Officer at Therigy, along with Khang Tran, PharmD, and Abbas Dewji, PharmD, presented the abstract Impact of Specialty Pharmacies on Stomatitis Prophylaxis with Dexamethasone at Everolimus Therapy Initiation on Wednesday, September 16.
This new poster highlights the effects of Dexamethasone on therapy adherence in Specialty Pharmacy patients. This abstract sheds light on the ability of Specialty Pharmacies to positively impact patients by introducing access to Dexamethasone, which was shown in a 2017 SWISH trial to decrease the incidence of stomatitis in patients on Everolimus therapy.
The abstract concludes patients starting Everolimus without Dexamethasone showed a significantly higher chance of early therapy discontinuation and patients that initially did not have Dexamethasone script had a 68.2% positive status change. Specialty pharmacies who are ensuring patients having a proper start of therapy are more likely to perform other services in maximizing patient’s outcomes.
You can download the study by filling out the pop up form to the right.
If you are interested in more information on outcomes or quality initiatives, learn more here.